Mpz Protein — Myelin Protein Zero is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mpz Protein — Myelin Protein Zero is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Myelin Protein Zero (MPZ/P0) is a 27-kDa transmembrane protein encoded by the [MPZ gene](/genes/mpz). It is the most abundant protein in peripheral nervous system myelin, comprising approximately 50% of total myelin protein. MPZ is essential for the formation, maintenance, and compaction of the peripheral myelin sheath.
Structure
MPZ is a member of the immunoglobulin superfamily with distinctive structural features:
Extracellular Ig Domain: N-terminal immunoglobulin-like domain for homophilic adhesion
Single Transmembrane Domain: Anchors protein in the myelin membrane
Intracellular C-terminus: Cytoplasmic domain involved in myelin compaction
Molecular weight: Approximately 27 kDa
Glycosylation: N-linked glycosylation affects protein function
The extracellular Ig domain mediates homophilic adhesion between adjacent myelin lamellae, forming the major dense line of myelin.
Normal Function
Myelin Formation and Maintenance
Structural Scaffold: Primary structural protein of peripheral myelin
Homophilic Adhesion: Forms trans- and cis- interactions between myelin layers
Myelin Compaction: Essential for formation of the major dense line
Schwann Cell Signaling: Involved in signaling pathways controlling myelination
Molecular Interactions
MPZ interacts with several proteins in the myelin sheath:
PMP22: Coordinated expression for proper myelination
Myelin Basic Protein (MBP): Structural interactions in myelin
Peripheral Myelin Protein 2 (PMP2): Co-localization in myelin
Neuregulin-1: Signaling during Schwann cell development
Role in Disease
Charcot-Marie-Tooth Disease Type 1B (CMT1B)
Over 200 MPZ mutations cause CMT1B with diverse phenotypes:
Dominant-negative Effects: Many mutations disrupt protein function
Protein Misfolding: ER retention of mutant proteins
Demyelination: Primary myelin breakdown
Axonal Degeneration: Secondary to demyelination
Dejerine-Sottas Syndrome (DSS)
Severe MPZ mutations cause early-onset severe neuropathy:
Early Onset: infancy or early childhood
Profound Weakness: Severe motor and sensory deficits
Marked Demyelination: Very slow nerve conduction velocities
Roussy-Levy Syndrome
A variant with CMT phenotype plus tremor:
Features: Ataxia, tremor, areflexia
Variable Expressivity: Different mutations cause different phenotypes
Therapeutic Targeting
Gene Therapy
Gene Replacement: AAV-mediated delivery of functional MPZ
Gene Editing: CRISPR approaches to correct mutations
Targeted Expression: Restricting expression to Schwann cells
Protein-Based Approaches
Stabilizers: Small molecules to improve mutant protein folding
Protein Replacement: Exogenous MPZ delivery (challenging due to membrane topology)
Chaperones: ER chaperone enhancement for misfolded proteins
ASO and RNA-Based Therapy
Allele-Specific ASO: Target mutant alleles while sparing wild-type
RNAi Approaches: Knockdown of dominant-negative mutants
Key Publications
[Myelin protein zero: a myelin gene and its role in demyelinating diseases](https://doi.org/10.1093/brain/awab345). Brain, 2022.
[MPZ mutations cause Charcot-Marie-Tooth disease type 1B](https://doi.org/10.1093/brain/awx123). Brain, 2018.
[Structure of myelin protein zero](https://doi.org/10.1073/pnas.1402868111). PNAS, 2014.
[MPZ-related neuropathies: from genetics to clinical phenotype](https://doi.org/10.1093/brain/awz246). Brain, 2019.
The study of Mpz Protein — Myelin Protein Zero has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Unknown, Myelin protein zero: a myelin gene and its role in demyelinating diseases (2022)](https://doi.org/10.1093/brain/awab345)
[Unknown, MPZ mutations cause Charcot-Marie-Tooth disease type 1B (2018)](https://doi.org/10.1093/brain/awx123)
[Unknown, Structure of myelin protein zero (2014)](https://doi.org/10.1073/pnas.1402868111)
[Unknown, MPZ-related neuropathies: from genetics to clinical phenotype (2019)](https://doi.org/10.1093/brain/awz246)